ASLAN Pharmaceuticals to Partner With BioGenetics on Commercialisation of Varlitinib in South Korea
26 févr. 2019 17h35 HE
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Feb. 27, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global...
ASLAN Announces Publication of New Pre-Clinical Data Demonstrating the Activity of Varlitinib in TNBC Cell Lines
23 janv. 2019 01h35 HE
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Jan. 23, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
ASLAN Pharmaceuticals to Present Positive varlitinib Data in First-Line Biliary Tract Cancer in Combination With Chemotherapy at ASCO GI
14 janv. 2019 17h44 HE
|
ASLAN Pharmaceuticals Limited
Objective Response Rate of 60% and Disease Control Rate of 100% observed in 300mg dose cohortData demonstrate increased activity of varlitinib in combination with gem/cis compared to standard of care ...
ASLAN Pharmaceuticals Announces Study Results from Phase 2 Study of Varlitinib in First-line Gastric Cancer
13 janv. 2019 17h30 HE
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Jan. 14, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
Aslan Pharmaceuticals to Participate in 30th Annual Piper Jaffray Healthcare Conference
20 nov. 2018 05h00 HE
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Nov. 20, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
ASLAN Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update
08 nov. 2018 06h05 HE
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Nov. 08, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
ASLAN Pharmaceuticals to Present New Data on ASLAN003 at American Society of Hematology Annual Meeting
01 nov. 2018 10h20 HE
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Nov. 01, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
ASLAN Pharmaceuticals Appoints Robert E. Hoffman as Independent Director
30 oct. 2018 03h54 HE
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Oct. 30, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
ASLAN Pharmaceuticals Enrolls First Subject in Phase 1 Study for ASLAN004 in Atopic Dermatitis
17 oct. 2018 12h31 HE
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Oct. 18, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT, Nasdaq: ASLN), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia...
ASLAN Pharmaceuticals Presents Two Posters on Varlitinib at Chinese Society of Clinical Oncology Annual Meeting
21 sept. 2018 04h00 HE
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Sept. 21, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...